Dr. Beuming leads the In Silico Drug Discovery Services at Latham Biopharm Group. He has more than 15 years of experience applying computational biophysics, computational chemistry, bioinformatics and cheminformatics to problems in biology and drug discovery, in academia and industry. Prior to joining LBG, he spent over a decade at Schrödinger, Inc, the global leader in providing computational chemistry and molecular modeling solutions to the biopharmaceutical and materials industries. He had a leading role in the Application Science department at Schrödinger, where he managed project and customer support to clients in the NY, NJ and PA region. He has supervised technology implementations in a variety of fields, including ligand and structure based small molecule discovery, and biologics research. He also made extensive contributions to Schrödinger’s in-house drug discovery projects, in his role as Research Leader in the Drug Discovery Applications Group. He has made key contributions to novel methodologies to key problems in computational chemistry, including the study of protein flexibility, protein solvation, thermodynamic binding affinity calculations, and small molecule and peptide docking. His work has been documented in over 50 peer-reviewed articles and reviews. He holds a Masters degree in Medicinal Chemistry from the Vrije Universiteit in Amsterdam, the Netherlands. He obtained his Ph.D. in Physiology and Biophysics from Weill Medical College at Cornell University, where he focused on elucidating structure function studies of neurotransmitter transporters. He serves as adjunct professor of Computational Biomedicine at Weill Medical College at Cornell University.
Zara joined Confo Therapeutics as Head of Computer-Aided Drug Discovery in 2020 and shortly thereafter was also appointed as Head of Informatics.
Zara has over 14 years of drug discovery experience. Prior to joining Confo Therapeutics, Zara worked at AstraZeneca where she applied cutting edge in silico approaches to support small molecule and biologic design activities against challenging neuroscience targets. In 2009, she was recruited by UCB BioPharma to develop and apply state-of-the-art computational approaches to enhance its CNS drug design and target assessment activities. Zara was instrumental in developing UCB’s membrane protein drug discovery capabilities, playing a key role in the design of GPCR clinical candidates.
Zara received a PhD in Computational Chemistry from the University of Nottingham (UK). Subsequently, she conducted postdoctoral research, gaining expertise in computational structural biology and molecular biophysics of membrane proteins at the University of Oxford (UK) in the Group of Prof. Mark Sansom.
Javier holds a PhD in Computational Chemistry from Universitat de Barcelona (UB). His thesis was co-directed by Professor Javier Luque and Enric Herrero. Javier accumulates 6 years of experience in computational chemistry and molecular modelling and he has been an active contributor to the development of PharmScreen and PharmQSAR since he joined the company. Javier is co-author in 5 chemistry publications and 1 patent.